April 17, 2018 / 12:37 PM / 5 days ago

BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine

April 17 (Reuters) - Merck & Co Inc:

* MERCK ANNOUNCES FIRST PHASE THREE STUDIES FOR PCV-15 (V114) ITS INVESTIGATIONAL PNEUMOCOCCAL DISEASE VACCINE

* MERCK - FIRST STUDY TO EVALUATE PCV-15 FOLLOWED BY PNEUMOCOCCAL VACCINE POLYVALENT ONE YEAR LATER IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER

* MERCK - SECOND PHASE 3 STUDY TO EVALUATE PCV-15 FOLLOWED BY PNEUMOCOCCAL VACCINE POLYVALENT GIVEN 8 WEEKS LATER IN ADULTS INFECTED WITH HIV Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below